Dr. Reddy’s Laboratories Presents Preclinical Data at SITC 2020 Demonstrating Significant Improvement in Tumor Growth Inhib...
November 09 2020 - 9:14AM
Business Wire
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE:
RDY, along with its subsidiaries together referred to as “Dr.
Reddy’s”) today announced a preclinical data presentation for E7777
(denileukin diftitox), its engineered IL-2-diphtheria toxin fusion
protein, at The Society for Immunotherapy of Cancer (SITC) 35th
Anniversary Annual Meeting, being held virtually.
Dr. Anil Namboodiripad, Senior Vice President and Head of Dr.
Reddy’s Proprietary Products Division stated, “We are encouraged
that in addition to the clinically demonstrated safety and activity
of denileukin diftitox in patients with cutaneous T cell lymphoma,
these new syngeneic mouse model studies show that E7777 also shows
promising activity as a potential immunotherapy agent for treatment
of solid tumors. Combination of E7777 with an anti-PD-1 agent
provided clear benefit both in terms of tumor growth control, and a
highly significant improvement in overall survival. We look forward
to conducting clinical trials to further explore this
combination.”
Key findings from the presentation are included below.
Title: E7777 (Denileukin Diftitox) Enhances Anti-Tumor Activity
and Significantly Extends Survival Benefit of Anti-PD-1 in
Syngeneic Solid Tumor Models
- E7777 administered as monotherapy inhibited tumor growth with
activity comparable to anti-PD-1 monotherapy in syngeneic murine
tumor models
- Combination of E7777 and anti-PD-1 inhibited tumor growth
substantially better than monotherapy treatments
- Administration of E7777 and anti-PD-1 for a limited treatment
period led to highly significant improvements in long-term
survival
- Combination of E7777 and anti-PD-1 was administration schedule
independent
Click here for link to the poster presented at the SITC 35th
Anniversary Annual Meeting
About Dr. Reddy’s: Dr. Reddy’s Laboratories Ltd. (BSE:
500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical
company, committed to providing affordable and innovative medicines
for healthier lives. Through its three businesses - Pharmaceutical
Services & Active Ingredients, Global Generics and Proprietary
Products – Dr. Reddy’s offers a portfolio of products and services
including APIs, custom pharmaceutical services, generics,
biosimilars and differentiated formulations. Our major therapeutic
areas of focus are gastrointestinal, cardiovascular, diabetology,
oncology, pain management and dermatology. Dr. Reddy’s operates in
markets across the globe. Our major markets include – USA, India,
Russia & CIS countries, and Europe. For more information, log
on to: www.drreddys.com
Disclaimer: This press release may include statements of future
expectations and other forward-looking statements that are based on
the management’s current views and assumptions and involve known or
unknown risks and uncertainties that could cause actual results,
performance or events to differ materially from those expressed or
implied in such statements. In addition to statements which are
forward-looking by reason of context, the words "may", "will",
"should", "expects", "plans", "intends", "anticipates", "believes",
"estimates", "predicts", "potential", or "continue" and similar
expressions identify forward-looking statements. Actual results,
performance or events may differ materially from those in such
statements due to without limitation, (i) general economic
conditions such as performance of financial markets, credit
defaults , currency exchange rates, interest rates, persistency
levels and frequency / severity of insured loss events, (ii)
mortality and morbidity levels and trends, (iii) changing levels of
competition and general competitive factors, (iv) changes in laws
and regulations and in the policies of central banks and/or
governments, (v) the impact of acquisitions or reorganization,
including related integration issues, and (vi) the susceptibility of our industry
and the markets addressed by our, and our customers’, products and
services to economic downturns as a result of natural disasters,
epidemics, pandemics or other widespread illness, including
coronavirus (or COVID-19), and (vii) other risks and uncertainties
identified in our public filings with the Securities and Exchange
Commission, including those listed under the "Risk Factors" and
"Forward-Looking Statements" sections of our Annual Report on Form
20-F for the year ended March 31, 2020. The company assumes no
obligation to update any information contained herein.”
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201109005652/en/
INVESTOR RELATIONS AMIT AGARWAL amita@drreddys.com (PH:
+91-40-49002135)
MEDIA RELATIONS APARNA TEKURI aparnatekuri@drreddys.com (PH: +91-40-
49002446)
Dr Reddys Laboratories (NYSE:RDY)
Historical Stock Chart
From Aug 2024 to Sep 2024
Dr Reddys Laboratories (NYSE:RDY)
Historical Stock Chart
From Sep 2023 to Sep 2024